ONC vs. REGN: A Head-to-Head Stock Comparison

Updated on October 5, 2025

Here’s a clear look at ONC and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

ONC trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, REGN is a standard domestic listing.

Symbol	ONC	REGN
Company Name	BeOne Medicines AG	Regeneron Pharmaceuticals, Inc.
Country	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	37.96 billion USD	62.50 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	February 3, 2016	April 2, 1991
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of ONC and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ONC vs. REGN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ONC	REGN
5-Day Price Return	-0.90%	-2.55%
13-Week Price Return	32.50%	7.10%
26-Week Price Return	41.02%	-12.16%
52-Week Price Return	20.61%	-46.08%
Month-to-Date Return	10.40%	-3.17%
Year-to-Date Return	90.60%	-21.07%
10-Day Avg. Volume	4.56M	1.22M
3-Month Avg. Volume	4.05M	1.13M
3-Month Volatility	51.09%	28.52%
Beta	0.78	0.30

Profitability

Return on Equity (TTM)

ONC

-6.58%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

ONC has a negative Return on Equity of -6.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

REGN

15.11%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ONC vs. REGN: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

ONC

-5.04%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ONC has a negative Net Profit Margin of -5.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

REGN

31.37%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

ONC vs. REGN: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

ONC

-2.03%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ONC has a negative Operating Profit Margin of -2.03%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

REGN

27.02%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ONC vs. REGN: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	ONC	REGN
Return on Equity (TTM)	-6.58%	15.11%
Return on Assets (TTM)	-3.87%	11.81%
Net Profit Margin (TTM)	-5.04%	31.37%
Operating Profit Margin (TTM)	-2.03%	27.02%
Gross Profit Margin (TTM)	85.37%	86.46%

Financial Strength

Current Ratio (MRQ)

ONC

1.94

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ONC’s Current Ratio of 1.94 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

REGN

4.60

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ONC vs. REGN: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

ONC

0.27

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

ONC’s Debt-to-Equity Ratio of 0.27 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

REGN

0.09

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ONC vs. REGN: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

ONC

-132.16

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

REGN

243.95

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.

ONC vs. REGN: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	ONC	REGN
Current Ratio (MRQ)	1.94	4.60
Quick Ratio (MRQ)	1.65	3.78
Debt-to-Equity Ratio (MRQ)	0.27	0.09
Interest Coverage Ratio (TTM)	-132.16	243.95

Growth

Revenue Growth

ONC vs. REGN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ONC vs. REGN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ONC

0.17%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC’s Dividend Yield of 0.17% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ONC vs. REGN: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

ONC

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ONC vs. REGN: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	ONC	REGN
Dividend Yield (TTM)	0.17%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ONC

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for ONC is currently unavailable.

REGN

13.97

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.97 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

ONC vs. REGN: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

ONC

9.25

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ONC’s P/S Ratio of 9.25 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

REGN

4.38

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.38 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ONC vs. REGN: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

ONC

8.16

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

ONC’s P/B Ratio of 8.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

REGN

1.89

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ONC vs. REGN: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	ONC	REGN
Price-to-Earnings Ratio (TTM)	--	13.97
Price-to-Sales Ratio (TTM)	9.25	4.38
Price-to-Book Ratio (MRQ)	8.16	1.89
Price-to-Free Cash Flow Ratio (TTM)	156.50	17.52